The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMERI.L Regulatory News (MERI)

  • There is currently no data for MERI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission - First day of dealing

6 Nov 2018 07:00

RNS Number : 4115G
Merian Chrysalis Investment Co. Ltd
06 November 2018
 

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area (other than the United Kingdom), Canada, Australia, Japan or the Republic of South Africa.

 

 

Merian Chrysalis Investment Company Limited

(the "Company")

 

First day of dealings

 

 

6 November 2018: Further to the announcement on 2 November 2018, Merian Chrysalis Investment Company Limited (the "Company") is pleased to announce that 100,000,000 Ordinary Shares will at 8.00 a.m. today be admitted to the premium segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). The Ordinary Shares will trade under the ticker: MERI (ISIN: GG00BGJYPP46).

 

In addition, the Company is pleased to announce that, to provide certainty to investors, the Investment Manager has agreed to cap the Company's ongoing charge expense ratio1 at 0.85% for the next 12 months or until the NAV reaches £200 million, whichever occurs earlier. This fee structure will be subject to review at the end of the 12 month period.

 

The total number of Ordinary Shares in the Company in issue immediately following Admission is 100,000,000 each with equal voting rights. The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. On Admission the Directors will, in aggregate, hold 0.07% of the issued share capital of the Company. PDMR Notifications are set out at the bottom of this announcement.

 

1 The ongoing charges expense ratio is calculated as the percentage the Company's annual running costs (excluding transaction costs and performance fees (if any) but including the annual management fees) represents of its net asset value.

 

For further information please contact:

 

Media contacts:

Ged Brumby, Smithfield Consultants

020 3047 2527

Olivia Evans, Smithfield Consultants

020 3047 2531

Amelie Shepherd, Merian Global Investors

020 7332 8345

Global Co-ordinator, Joint Bookrunner, Sponsor and Financial Adviser:

Liberum

020 3100 2000

Gillian Martin, Andrew Davies, Christopher Britton, Louis Davies

Joint Bookrunner:

Zeus

020 3829 5000

John Goold, Rupert Woolfenden

Merian Global Investors:

MGI is a leading, independent, global asset management firm. It is focused on delivering strong investment performance and customer-focused investment solutions that result in positive long-term outcomes. The business had assets under management of £34.4 billion, as at 31 July 2018.

 

Further information on the Company can be found on its website at www.Merian.com/Chrysalis

 

The Company's LEI is: 213800F9SQ753JQHSW24

 

Save for expressions defined in this announcement, words and expressions defined in the Prospectus shall have the same meaning in this announcement.

 

Important Notice

 

This announcement has been issued by and is the sole responsibility of the Company. Liberum Capital Limited and Zeus Capital Limited, each of which are authorised and regulated by the Financial Conduct Authority in the United Kingdom, are acting only for the Company in connection with the matters described in this announcement and are not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of each of them or advice to any other person in relation to the matters contained herein. Neither Liberum, Zeus nor any of its or their respective affiliates, directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for this announcement, its contents or otherwise in connection with it or any other information relating to the Company, whether written, oral or in a visual or electronic format.

 

This announcement may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and will not be offered, sold, exercised, resold, transferred or delivered, directly or indirectly, in or into the United States or to, or for the account or benefit of, any US person (as defined under Regulation S under the US Securities Act). The Company has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended.

 

Neither this announcement nor any copy of it may be: (i) taken or transmitted into or distributed in any member state of the European Economic Area (other than the United Kingdom), Canada, Australia or the Republic of South Africa or to any resident thereof, or (ii) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this announcement in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Andrew Haining

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

30,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

30,000

£1.00

£30,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Stephen Coe

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

25,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

25,000

£1.00

£25,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Simon Holden

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

15,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

15,000

£1.00

£15,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

This announcement is made in accordance with the requirements of the EU Market Abuse Regulation ("MAR") and the Company confirms that the PDMR's notification obligations under MAR have also been satisfied.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFKPDPFBDDCDK
Date   Source Headline
19th Mar 202012:09 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
18th Mar 20202:51 pmRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
9th Mar 20204:36 pmRNSPrice Monitoring Extension
28th Feb 20204:05 pmRNSResult of AGM
17th Feb 20203:11 pmRNSCorporate Update
30th Jan 20207:00 amRNSNotice of AGM
24th Jan 20207:00 amRNSFinal Results
15th Jan 20203:46 pmRNSAppointment of Senior Independent Director
15th Jan 20207:00 amRNSPortfolio Update
11th Dec 20197:00 amRNSPortfolio Update
3rd Dec 20197:00 amRNSNet Asset Value(s)
27th Nov 20197:00 amRNSPortfolio Update
23rd Oct 20197:00 amRNSPortfolio Update
1st Oct 20199:21 amRNSHolding(s) in Company
27th Sep 20194:49 pmRNSHolding(s) in Company
27th Sep 20193:47 pmRNSHolding(s) in Company
27th Sep 20193:46 pmRNSHolding(s) in Company
27th Sep 201912:46 pmRNSHolding(s) in Company
27th Sep 20197:00 amRNSHolding(s) in Company
26th Sep 20198:00 amRNSPDMR shareholdings
25th Sep 20193:16 pmRNSHolding(s) in Company
25th Sep 20193:12 pmRNSDirector Declaration
24th Sep 20197:00 amRNSResult of Placing under Placing Programme
20th Sep 20197:00 amRNSPlacing Update
18th Sep 20197:00 amRNSAnnouncement of Placing Price
10th Sep 20197:00 amRNSPlacing under Placing Programme
30th Aug 20197:00 amRNSNet Asset Value(s)
16th Aug 20197:00 amRNSPortfolio Update
6th Aug 20192:20 pmRNSPortfolio Update
4th Jul 20197:00 amRNSPortfolio Update
28th Jun 20196:31 pmRNSHalf-year Report
20th Jun 20197:00 amRNSCorporate Update
31st May 20197:00 amRNSNet Asset Value(s)
7th May 20193:55 pmRNSHolding(s) in Company
26th Apr 20193:36 pmRNSHolding(s) in Company
24th Apr 20191:10 pmRNSHolding(s) in Company
24th Apr 20191:08 pmRNSHolding(s) in Company
24th Apr 20191:06 pmRNSHolding(s) in Company
18th Apr 20194:52 pmRNSDirector/PDMR Shareholding
18th Apr 20191:43 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSResult of Placing under Placing Programme
15th Apr 20197:00 amRNSPlacing Update
12th Apr 20198:46 amRNSProposed Placing Price
12th Apr 20198:45 amRNSPortfolio Update
26th Mar 20197:00 amRNSPlacing under Placement Programme
5th Mar 20197:00 amRNSNAV Announcement and Portfolio Update
22nd Feb 20191:22 pmRNSStarling Bank awarded CIF Pool A grant
13th Feb 20197:00 amRNSPortfolio Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.